(TELESUR) – This protein increases its concentration during viral infections and inflammatory processes.
“It is an immunomodulatory peptide, derived from the cellular stress response protein, known as HSP60. This molecule was designed by bioinformatic tools and is obtained by chemical synthesis,” affirmed CIGB’s researcher Dr. Gillian Martinez Donato.
According to Martinez, CIGB-258 operates in the regulation of the immune system. This protein increases its concentration during viral infections and inflammatory processes.
The CIGB requested the use of CIGB-258 in COVID confirmed patients in the severe and critical stages. Since May 5, 31 patients had received therapy with this peptide.
As Donato explained, 12 patients started CIGB-258 therapy intheir severe stages and 19 in the critical disease phase. In the first group, survival was 92 percent, while in the second group it was 73 percent.